科研之友
微信
新浪微博
Facebook
分享链接
摘要
ContextType 2 diabetes has reached epidemic proportions and places a heavy burden on society. Dapagliflozin is a novel treatment choice for type 2 diabetes. ObjectiveA meta-analysis of randomized controlled trials (RCTs) was conducted to assess the efficacy and safety of dapagliflozin treatment. Data SourcesMedline (via PubMed), Embase (via OVID) and the Cochrane Library (up to August 2012) were searched, and RCTs were collected. Study SelectionStudies included type 2 diabetic subjects, who had been treated with dapagliflozin, and recorded HbA(1c) as outcomes. Data ExtractionTwo reviewers independently assessed articles and study quality. Patient characteristics, interventions and outcomes were collected. Data SynthesisTen RCTs were included. Risk of bias for outcomes was low. Fixed or random effects models were used to pool the results. Dapagliflozin treatment was associated with a reduction in HbA(1c) [weighted mean difference (WMD): -0.53%; 95% confidence interval (CI): -0.58% to -0.47%; p<0.00001], fasting plasma glucose (WMD: -1.06mmol/L; 95% CI: -1.20, -0.92; p<0.00001), and body weight (WMD: -1.63kg; 95% CI: -1.83, -1.43; p<0.00001). Dapagliflozin monotherapy did not lead to hypoglycaemia [relative risk (RR): 1.44; 95% CI: 0. 86, 2.41; p=0.17], although hypoglycaemic risk increased (RR: 1.16; 95% CI: 1.05, 1.29; p=0.005) when dapagliflozin was combined with other hypoglycaemic drugs. Dapagliflozin increased urinary glucose excretion (WMD: 26.98; 95% CI: 21.72, 32.24; p<0.00001) and was associated with an increased risk of urinary tract infections (RR: 1.33; 95% CI: 1.10, 1.60; p=0.004) and genital tract infections (RR: 3.23; 95% CI: 2.50, 4.18; p=0.00001). ConclusionsDapagliflozin appears to be an effective treatment for type 2 diabetes, although it may increase the risk of urinary tract infections and genital tract infections.
